Clinical trials: tuberculosis
Tuberculosis (TB), Tuberculosis Infection, Latent
Screening With Portable X-rays for Rapid Recognition of TB
SPOT-TB (Screening with Portable X-rays for rapid recOgniTion of TB) is a prospective study evaluating a community-based tuberculosis (TB) screening strategy for migrant populations in New York City.
- Conditions
- Tuberculosis (TB), Tuberculosis Infection, Latent, HIV (Human Immunodeficiency Virus)
- Trial name
- SPOT-TB (NCT07737275)
- Testing
- Mobile chest radiography for tuberculosis screening
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
Tuberculosis
Evaluation of Tuberculosis Treatment Outcomes
Tuberculosis (TB) is an infectious disease caused by Mycobacterium species grouped in the Mycobacterium tuberculosis complex. TB remains a major global health problem, despite the fact that there are drugs that can eradicate the…
- Trial name
- CLIO-TB (NCT06942975)
- Testing
- Patients with turberculosis
- Where
- Italy
- Volunteers
- 111 people
- Sponsor
- Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Tuberculosis
Development of a Rapid and Accurate Diagnostic Assay for Tuberculosis
This study evaluates new technique for diagnosis of tuberculosis. Among patients who are suspected with tuberculosis, participants will be tested conventional method including Xpert TB/RIF assay, and new diagnostic technique…
- Trial name
- NCT03423550
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Asan Medical Center
AIDS, Tuberculosis
Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin
The object of this study is to evaluate the pharmacokinetic interactions, short term safety and efficacy of standard dose lopinavir/ritonavir 200mg/50 (two tablets twice daily) given with ritonavir 100 mg three tablets twice…
- Trial name
- NCT01700790
- Testing
- Lopinavir/ritonavir and ritonavir
- Where
- Brazil
- Volunteers
- 9 people
- Sponsor
- University of Miami
Tuberculosis, HIV
Start TB Patients on ART and Retain on Treatment (START Study)
The purpose of the START Study is to identify an effective, cost-effective, acceptable intervention that addresses programmatic, structural and psychosocial barriers to ART initiation and retention during TB treatment, with the…
- Trial name
- START (NCT01872390)
- Testing
- Combination Intervention Package, Standard of Care
- Where
- 12 sites in Lesotho
- Volunteers
- 415 people
- Sponsor
- Columbia University
Tuberculosis
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
This study aims to find the proposed dose of Rifapentine (RPT) taken once daily with Isoniazid (INH) for 28 days to prevent tuberculosis (TB).
- Trial name
- NCT07124559
- Testing
- Rifapentine, Isoniazid, Dolutegravir
- Where
- 11 sites in Botswana, Haiti and 4 more
- Volunteers
- 144 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Pulmonary TB
Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis
Acquired Rifampicin Resistance has emerged as an important issue in the treatment of HIV-TB patients. It has not been a major problem in HIV-negative individuals treated for TB treated with standard intermittent regimens.
- Trial name
- NCT00933790
- Testing
- ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)
- Where
- 3 sites in India
- Volunteers
- 331 people
- Sponsor
- Tuberculosis Research Centre, India
HIV Infections, Tuberculosis
TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen
Primary objective: To determine the rate of confirmed treatment failure and relapse with an intermittent rifabutin-based regimen for the treatment of isoniazid and rifamycin-susceptible HIV-related tuberculosis (TB).
- Trial name
- NCT00023361
- Testing
- Rifabutin
- Where
- 23 sites in United States, Canada
- Volunteers
- 215 people
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections
Evaluation of Three Regimens of Chemoprophylaxis for Tuberculosis in Patients co-Infected by HIV and Mycobacterium Tuberculosis
To evaluate adherence and safety of three regimens of chemoprophylaxis for tuberculosis (TB) in HIV-infected patients with positive tuberculin skin test.
- Trial name
- NCT00402454
- Testing
- isoniazid, rifampin + isoniazid or rifampin + pyrazinamide
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Sociedad Andaluza de Enfermedades Infecciosas
Opportunistic Infections, HIV-Related, Cryptococcal Infections
Evaluation of Advanced HIV Disease Differentiated Care Model in Malawi
This study will evaluate the implementation of an enhanced package of care, CD4 and tuberculosis lipoarabinomannan (TB-LAM) tests and the initiation of patients on TB prophylaxis [TPT and CPT], on retention in care and viral…
- Conditions
- Opportunistic Infections, HIV-Related, Cryptococcal Infections, AIDS With Tuberculosis, AIDS-related Kaposi Sarcoma
- Trial name
- NCT05510973
- Testing
- Enhanced package for AHD care
- Where
- 13 sites in Malawi
- Volunteers
- 700 people
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
Healthy Volunteers
The Effect of PAS on the Pharmacokinetics of Tenofovir in Healthy Subjects
The main purpose of this study is to evaluate whether PAS will change the PK parameters of tenofovir.
- Trial name
- NCT03070405
- Testing
- Tenofovir disoproxil fumarate 300mg, Para-aminosalicylic acid Ca granule 5.28 g
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Inje University
Tuberculosis, Skin Tests
Tolerability and Reactogenicity Trial of the Recombinant Tuberculosis Allergen in Healthy Volunteers
Primary objective of the trial is to study the safety and tolerability of the Recombinant tuberculosis allergen in standard dilution in healthy volunteers after a single dose.
- Trial name
- NCT05398562
- Testing
- Mycobacterial recombinant allergens 0.1 μg, Mycobacterial recombinant allergens 0.2 μg
- Where
- Russia
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Cystic Fibrosis, Hepatitis A
Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively
CF patients are at risk for hepatic disease. Vaccination is recommended to all CF patients according to European consensus. The aim of the study is to vaccinate as many patients as possible and to follow up whether immunization…
- Conditions
- Cystic Fibrosis, Hepatitis A, Hepatitis B, Tuberculosis
- Trial name
- NCT02605538
- Testing
- Vaccination with vaccine against hepatitis A and B
- Where
- Sweden
- Volunteers
- healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
Tuberculosis, HIV Infections
Tuberculosis in HIV Infected Patients in Uganda
This was a clinical trial in HIV infected patients with tuberculosis. The study assessed whether the addition of prednisolone, a type of steroid medication, to the standard treatment for tuberculosis improved immune and viral…
- Trial name
- NCT00057421
- Testing
- prednisolone
- Where
- Uganda
- Volunteers
- 190 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes Mellitus, Latent Tuberculosis Infection
Prospective Quality Improvement Project for High-Risk Diabetes Patients
Diabetes is the most important comorbidity of tuberculosis patients in Taiwan, and 1/4 of tuberculosis patients also It is a diabetic patient, and the treatment of latent tuberculosis infection is currently an important policy of…
- Conditions
- Diabetes Mellitus, Latent Tuberculosis Infection, Continuous Glucose Monitoring, Quality of Life
- Trial name
- NCT06472609
- Testing
- enhanced interactive education
- Where
- Taiwan
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University WanFang Hospital
Tuberculosis
A Phase I Study of Safety & Immunogenicity of AERAS-456 in HIV-Neg. Adults Treated for Drug-susceptible Pulmonary TB
This is a Phase I, double-blind, randomized, placebo-controlled safety and immunogenicity study in adults who have recently been successfully treated for drug-susceptible pulmonary Tuberculosis (TB).
- Trial name
- C-037-456 (NCT02375698)
- Testing
- H56:IC31
- Where
- 3 sites in South Africa
- Volunteers
- 22 people
- Sponsor
- Aeras
Drug-Induced Liver Injury, Anti-Tuberculous Drug Reaction
Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients
A panel of highly sensitive circulating biomarkers for acute liver injury have been identified and demonstrated to identify liver injury on first presentation to hospital before standard tests are elevated in patients with…
- Conditions
- Drug-Induced Liver Injury, Anti-Tuberculous Drug Reaction, Tuberculosis
- Trial name
- ALISTER (NCT03211208)
- Where
- United Kingdom
- Volunteers
- 194 people
- Sponsor
- University of Edinburgh
Tuberculosis, Pulmonary
Accuracy and Feasibility of Xpert Ultra
Consenting adults presenting with signs and symptoms compatible with pulmonary tuberculosis will be interviewed for demographic and medical information, and then will be asked to provide 3-4 expectorated sputum specimens.
- Trial name
- NCT03072576
- Testing
- Xpert MTB/RIF Ultra
- Where
- 6 sites in Belarus, Georgia and 2 more
- Volunteers
- 1,400 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Tuberculosis
Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19
Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for treating patients with Multidrug-resistant TB and patient with both Multidrug-resistant TB…
- Trial name
- NCT05077813
- Testing
- 13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB), 9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB), All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)
- Where
- 2 sites in Egypt, Saudi Arabia
- Volunteers
- 250 people
- Sponsor
- Kafrelsheikh University
Tuberculosis, Latent
Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB
A seamless, staged Phase II/III, open-label, multicenter, non-inferiority trial, to compare the efficacy and safety of 4 weeks of bedaquiline (BDQ) versus a a standard regimen for preventing regimen for preventing confirmed or…
- Trial name
- BREACH-TB (NCT06568484)
- Testing
- Bedaquiline, Isoniazid, rifapentine, Levofloxacin
- Where
- 8 sites in Mongolia, Peru and 2 more
- Volunteers
- 2,530 people
- Sponsor
- Johns Hopkins University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.